Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?

Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?

Code: FW-20150206 | Published: Feb-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight the potential cost of treatment to the US healthcare system associated with a new class of dyslipidaemia therapies called PCSK9 inhibitors. The two most advanced drugs in this class - Sanofi and Regeneron Pharmaceuticals alirocumab and Amgens evolocumab - are widely expected to gain FDA approval during the second half of 2015.

Two key points arise from CVS eye-watering assertion that the PCSK9 class could cost the US system up to $150 billion a year; whether such public assessments are now the new normal in a post-Sovaldi payer environment and whether anticipated physician usage of these new drugs supports the estimation provided by CVS? - ViewPoints: CVS Health gets the math wrong, but is it the thought that counts?

Feedback sourced from physicians by FirstWord over the past few years indicates that the cost estimate provided by CVS represents a worst-case scenario by some margin. Nevertheless, we thought it useful to poll US-based cardiologists this week in light of the potential significance that payer stance towards the PCSK9s could have on these anticipated blockbuster products and potentially other drug classes.








Specifically we are asking US-based cardiologists:


Despite the broad popularity of this drug class, there remains significant scope to optimise the use of statin therapy in patients who may initially be deemed intolerant or who may be presumed unlikely to reach LDL goal with a statin.
- Completely disagree
- Disagree
- Somewhat disagree
- Neither agree or disagree
- Somewhat agree
- Agree
- Completely agree

Thinking about launch of the first PCSK9 inhibitors later this year, PBMs and other payers will be right to attempt to limit access by requiring laboratory tests to show evidence of muscle inflammation or liver damage before allowing treatment to those deemed statin intolerant.
- Completely disagree
- Disagree
- Somewhat disagree
- Neither agree or disagree
- Somewhat agree
- Agree
- Completely agree

Recently introduced guidelines from the American Heart Association and American College of Cardiology - which suggest that those patients who have had a previous cardiac event should be treated initially with high-dose statins to lower cholesterol as much as possible - will significantly increase my use of the PCSK- inhibitor class among patients with a history of coronary artery disease.
- Completely disagree
- Disagree
- Somewhat disagree
- Neither agree or disagree
- Somewhat agree
- Agree
- Completely agree

Assuming that outcomes studies demonstrate positive results, to what percentage of patients with heterozygous familial hypercholesterolaemia (HeFH) would you expect to prescribe a PCSK9 inhibitor (at peak usage)?


Excluding uncertainty as to whether the PCSK9 inhibitor class will demonstrate a cardiovascular outcomes benefit (data should be available in the 2017-2018 timeframe), what would act as the primary reason for you not to prescribing one of these drugs?
- Sub-optimal use of statin therapy
- Injectable administration of PCSK9s
- Cost
- Unfamiliarity with drug class
- Other (please state)



Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord